| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainNCT06325566 | MESO | Phase 3 | Active not recruiting | 2027-07Estimated |
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisNCT06328777 | Cabaletta Bio | Phase 2, Phase 3 | Recruiting | 2029-07Estimated |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 | AVLN | Phase 2 | Active not recruiting | 2027-06Estimated |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerNCT06331299 | URGN | Phase 3 | Completed | 2025-09-11Actual |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 | vTv Therapeutics | Phase 3 | Active not recruiting | 2027-04Estimated |
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 | Acumen Pharmaceuticals | Phase 2 | Active not recruiting | 2026-10-29Actual |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)NCT06340360 | NKTR | Phase 2 | Completed | 2025-11-26Actual |
| ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)NCT06342947 | Aligos Therapeutics | Phase 2 | Completed | 2024-08-19Actual |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067 | ERAS | Phase 3 | Active not recruiting | 2028-04Estimated |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003 | Arrowhead Pharmaceuticals | Phase 3 | Completed | 2026-06-12Actual |
| Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016 | Arrowhead Pharmaceuticals | Phase 3 | Completed | 2026-06-17Actual |
| Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133 | Arrowhead Pharmaceuticals | Phase 3 | Completed | 2026-06-01Actual |
| A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)NCT06347159 | EWTX | Phase 2 | Active not recruiting | 2027-12Estimated |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)NCT06358651 | VTGN | Phase 3 | Completed | 2025-10-31Actual |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)NCT06358950 | Alkermes, Inc. | Phase 2 | Completed | 2025-06-19Actual |
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT PromoterNCT06359379 | Shuttle Pharmaceuticals, Inc. | Phase 2 | Terminated | 2025-12-01Actual |
| Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 | AXSM | Phase 3 | Completed | 2024-12-31Actual |
| A Study of Barzolvolimab in Patients With Prurigo NodularisNCT06366750 | Celldex Therapeutics | Phase 2 | Active not recruiting | 2026-03-17Actual |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285 | PBYI | Phase 2 | Recruiting | 2027-12-30Estimated |
| A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"NCT06374797 | CALC | Phase 2 | Terminated | 2026-04-06Actual |
| Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyNCT06377930 | RAPP | Phase 2 | Completed | 2025-09-26Actual |
| A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque PsoriasisNCT06380907 | Zai Lab (Hong Kong), Ltd. | Phase 2 | Terminated | 2025-12-16Actual |
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976 | Kyverna Therapeutics | Phase 2 | Active not recruiting | 2027-04Estimated |
| Dusquetide for the Treatment of Behcet's DiseaseNCT06386744 | Soligenix | Phase 2 | Completed | 2025-05-23Actual |
| Namodenoson Treatment of Advanced Pancreatic CancerNCT06387342 | Can-Fite BioPharma | Phase 2 | Recruiting | 2026-07-15Estimated |
| A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseaseNCT06388083 | BLTE | Phase 2, Phase 3 | Active not recruiting | 2028-02Estimated |
| A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200 | Ocugen | Phase 3 | Active not recruiting | 2027-02-12Estimated |
| A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseNCT06389214 | ALDX | Phase 3 | Completed | 2024-06-11Actual |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaNCT06389292 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2028-05-25Estimated |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059 | NVCR | Phase 2 | Completed | 2025-11-18Actual |
Trial details
- Registry ID
- NCT06325566
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06328777
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06329401
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06331299
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06334133
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06335173
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06340360
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06342947
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06346067
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06347003
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06347016
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06347133
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06347159
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06358651
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06358950
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06359379
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06360419
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06366750
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06369285
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06374797
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06377930
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06380907
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06384976
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06386744
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06387342
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06388083
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06388200
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06389214
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06389292
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06390059
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.